Immunohistochemical expression of CD8, CTLA4, and PD-L1 in NSCLC of smokers versus non smokers and its effect on prognosis

Pub Date : 2022-08-02 DOI:10.1080/20905068.2022.2101083
R. Elsaka, S. Helal, A. Abdelhady, Nourhan. M. Kolaib, Manal. A. Soliman
{"title":"Immunohistochemical expression of CD8, CTLA4, and PD-L1 in NSCLC of smokers versus non smokers and its effect on prognosis","authors":"R. Elsaka, S. Helal, A. Abdelhady, Nourhan. M. Kolaib, Manal. A. Soliman","doi":"10.1080/20905068.2022.2101083","DOIUrl":null,"url":null,"abstract":"ABSTRACT Background Identifying hig- risk non-small cell lung cancer (NSCLC) patients is the most contentious area in lung pathology for reducing cancer-related morbidity and mortality. Aim of the work Was to investigate the immunohistochemical expression of CD8, CTLA4, and PD-L1 among different NSCLC histopathological variants and it’s correlation with different clinicopathological variables. Material and Methods Expression of CD8, CTLA4, & PD-L1 was evaluated immunohistochemically in 45 NSCLC cases. Results Higher expression of CD8 tumor infiltrating lymphocytes (TILs) was significantly associated with better progression-free survival (PFS). The expression of CTLA4&PD-L1 on tumor cells was significantly associated with lower PFS. However, smoking status of the studied cases showed no statistically significant correlation with expression of any of the studied immunohistochemical markers. Conclusions Immunostaining for CD8, CTLA4, and PD-L1 could have a major role in the anticipation of PFS of NSCLC cases regardless of their smoking status.","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20905068.2022.2101083","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

ABSTRACT Background Identifying hig- risk non-small cell lung cancer (NSCLC) patients is the most contentious area in lung pathology for reducing cancer-related morbidity and mortality. Aim of the work Was to investigate the immunohistochemical expression of CD8, CTLA4, and PD-L1 among different NSCLC histopathological variants and it’s correlation with different clinicopathological variables. Material and Methods Expression of CD8, CTLA4, & PD-L1 was evaluated immunohistochemically in 45 NSCLC cases. Results Higher expression of CD8 tumor infiltrating lymphocytes (TILs) was significantly associated with better progression-free survival (PFS). The expression of CTLA4&PD-L1 on tumor cells was significantly associated with lower PFS. However, smoking status of the studied cases showed no statistically significant correlation with expression of any of the studied immunohistochemical markers. Conclusions Immunostaining for CD8, CTLA4, and PD-L1 could have a major role in the anticipation of PFS of NSCLC cases regardless of their smoking status.
分享
查看原文
CD8、CTLA4和PD-L1在吸烟者与非吸烟者非小细胞肺癌中的免疫组织化学表达及其对预后的影响
背景识别高危非小细胞肺癌癌症(NSCLC)患者是肺部病理学中最具争议的降低癌症相关发病率和死亡率的领域。本工作的目的是研究CD8、CTLA4和PD-L1在不同NSCLC组织病理学变体中的免疫组织化学表达,以及与不同临床病理变量的相关性。材料与方法用免疫组化方法检测45例非小细胞肺癌组织中CD8、CTLA4和PD-L1的表达。结果CD8肿瘤浸润性淋巴细胞(TIL)的高表达与较好的无进展生存期(PFS)显著相关。CTLA4和PD-L1在肿瘤细胞上的表达与较低的PFS显著相关。然而,研究病例的吸烟状况与任何研究的免疫组织化学标志物的表达没有统计学上的显著相关性。结论CD8、CTLA4和PD-L1的免疫染色可能在预测NSCLC患者的PFS中发挥重要作用,无论其吸烟状况如何。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信